Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Pharm Ther ; 43(6): 807-812, 2018 Dec.
Article in English | MEDLINE | ID: mdl-29800494

ABSTRACT

WHAT IS KNOWN AND OBJECTIVE: Benzodiazepines are widely consumed in prisons, despite the iatrogenic risks associated with this therapeutic class. A multidisciplinary pharmacotherapy programme was therefore initiated by pharmacists in 2001. The aim of this study was to demonstrate the efficacy of teamwork between psychiatrists and pharmacists in benzodiazepine dose adjustment, with 15 years of hindsight. METHOD: In this retrospective study, daily prescribed benzodiazepine doses were compared between a reference group of patients in prisons in Lyon, France, in 2000, and four groups after psychiatrist-pharmacist teamwork in 2004, 2008, 2012 and 2016. RESULTS AND DISCUSSION: A number of 1249 patients were included. Prescribed doses of benzodiazepine decreased in the intervention groups, to a mean of 29-35 mg diazepam equivalent per day, compared to the control group (42 mg/day) (P < .001). The first 4-year period (2000-2004) demonstrated that monthly meetings and systematic pharmaceutical medication review had an impact on prescribed benzodiazepines, limiting consumed doses. The others (2004-2008, 2008-2012 and 2012-2016) confirmed that physicians' adherence to prescription guidelines and the efficacy of pharmacotherapy programme was maintained, particularly in those inmates taking high doses. WHAT IS NEW AND CONCLUSION: A continuous quality programme conducted by psychiatrists and pharmacists showed positive impact in reducing doses of benzodiazepine prescribed to prisoner patients and contributing to reduce risk of benzodiazepine-related problems.


Subject(s)
Benzodiazepines/administration & dosage , Pharmacists/organization & administration , Practice Patterns, Physicians'/standards , Prisoners , Adult , Dose-Response Relationship, Drug , Female , France , Guideline Adherence , Humans , Male , Patient Care Team/organization & administration , Practice Guidelines as Topic , Psychiatry/organization & administration , Retrospective Studies , Time Factors
2.
Ann Pharm Fr ; 67(6): 408-13, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19900604

ABSTRACT

Benzodiazepines are potentially addictive drugs: psychological and physical dependence can develop within a few weeks or years of regular or repeated use. The socioeconomic costs of the present high level of long-term benzodiazepine use are considerable. These consequences could be minimised if prescriptions for long-term benzodiazepines were decreased. However, many physicians continue to prescribe benzodiazepines and patients wishing to withdraw receive little advice or support. Particular care should be taken in prescribing benzodiazepines for vulnerable patients such as elderly persons, pregnant women, children, alcohol- or drug-dependent patients and patients with comorbid psychiatric disorders. The following update gives recent research results on the withdrawal pathophysiology and practical information in order to treat or prevent benzodiazepine withdrawal syndrome.


Subject(s)
Benzodiazepines/adverse effects , Substance Withdrawal Syndrome/psychology , Substance-Related Disorders/psychology , Adult , Aged , Aging/psychology , Alcoholism/complications , Female , Humans , Male , Mental Disorders/complications , Middle Aged , Pregnancy , Substance Withdrawal Syndrome/therapy , Substance-Related Disorders/rehabilitation
SELECTION OF CITATIONS
SEARCH DETAIL
...